|
|
|
|
| LEADER |
00000cam a22000007a 4500 |
| 001 |
on1405367983 |
| 003 |
OCoLC |
| 005 |
20240909213021.0 |
| 006 |
m o d |
| 007 |
cr cnu|||||||| |
| 008 |
231021s2023 sz a ob 001 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|c EBLCP
|d YDX
|d GW5XE
|d EBLCP
|d YDX
|d OCLCO
|d OCLCF
|d OCLCQ
|d OCLCO
|d UKAHL
|
| 019 |
|
|
|a 1405188387
|
| 020 |
|
|
|a 9783031403712
|
| 020 |
|
|
|a 3031403711
|
| 020 |
|
|
|z 3031403703
|
| 020 |
|
|
|z 9783031403705
|
| 024 |
7 |
|
|a 10.1007/978-3-031-40371-2
|2 doi
|
| 035 |
|
|
|a (OCoLC)1405367983
|z (OCoLC)1405188387
|
| 050 |
|
4 |
|a RM315
|b .B45 2023
|
| 049 |
|
|
|a HCDD
|
| 100 |
1 |
|
|a Belmaker, Robert Haim,
|e author.
|
| 245 |
1 |
0 |
|a Psychopharmacology reconsidered
|h [electronic resource] :
|b a concise guide exploring the limits of diagnosis and treatment /
|c Robert Haim Belmaker, Pesach Lichtenberg.
|
| 260 |
|
|
|a Cham, Switzerland :
|b Springer,
|c [2023]
|
| 300 |
|
|
|a 1 online resource (xiv, 220 pages) :
|b illustrations
|
| 500 |
|
|
|a Description based upon print version of record.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a Intro -- Acknowledgements -- Contents -- Chapter 1: Introduction -- References -- Chapter 2: The Biochemical Basis for Psychopharmacology in the Brain Synapse: Are We Looking in the Right Place? -- Reference -- Chapter 3: Are DSM or ICD Diagnoses the Basis for Scientific Use of Psychopharmacologic Drugs? -- References -- Chapter 4: The Clinical Control Trial in Psychiatry: What It Is, What It Has Been, and Does It Have a Future? -- Post-hoc Analyses -- Acute Trials, Prevention Trials, "Survival Trials" and Crossover Trials
|
| 505 |
8 |
|
|a The Role of the Clinical Trial in the Teaching of Psychopharmacology -- Individual Differences -- Advice for the Clinical Reader of Controlled Trials -- Add-On Vs. Placebo Controlled Trials -- The Role of Guidelines -- Pathways for the Future -- References -- Chapter 5: Antidepressant Drugs: For Anyone Sad or Only for the Melancholic Depressed? -- Maintenance Treatment with Antidepressants -- The Development of SSRIs AND SNRIs -- The Monoamine Theories of Depression -- Monoamine Oxidase Inhibitors -- Bipolar Depression -- Antidepressants in Panic Disorder
|
| 505 |
8 |
|
|a Switching Antidepressants in Treatment Resistance -- Cortisol and Depression -- Side Effects -- Pregnancy and Lactation -- Animal Models and Depression Psychopharmacology -- Stimulants in Depression -- Antidepressants in Depression After Myocardial Infarction -- Antidepressants and COVID-19 -- Psychological Effects of Antidepressant Treatment -- Clinical Vignettes -- References -- Chapter 6: Antipsychotic Drugs: Do They Define Schizophrenia or Do They Blunt All Emotions? -- Rating Scales -- Pharmacodynamics -- The Disease Model -- Mechanisms of Action -- The Dopamine Hypothesis
|
| 505 |
8 |
|
|a New Antipsychotics -- Philosophy of Antipsychotic Treatment -- Doses -- Side Effects -- Clinical Vignettes -- References -- Chapter 7: Antianxiety Medications: Are They Addictive or Are They Mankind's Precious Heritage? -- Historical Background -- The Nonlinear Nature of Anti-anxiety Treatment -- Alcohol as a Proto Anti-anxiety Drug -- Non-barbiturate Sedatives -- Benzodiazepines -- The Mechanism of Action of Benzodiazepines -- The Z Drugs -- Comparison of Treatment of Anxiety with Benzodiazepines Vs. Antidepressants -- Side Effects -- Sleep Architecture
|
| 505 |
8 |
|
|a Benzodiazepine Use in Psychiatry-Related Medicine -- Pregnancy and Lactation -- Clinical Vignettes -- References -- Chapter 8: Mood Stabilizers: Off the Gold Standard? -- Pharmacokinetics and Pharmacodynamics -- Efficacy of Lithium in Bipolar Disorder -- Carbamazepine -- Valproic Acid -- Mood Stabilizers -- Antipsychotics as Mood Stabilizers -- Administration of Lithium -- The Importance of Patient History -- Suicidality -- Individual Differences and Prediction of Lithium Response in Bipolar Disorder -- Toxicity -- Side Effects -- Polyuria and Polydipsia -- Tremor
|
| 500 |
|
|
|a Mood Stabilizers in Schizoaffective Disorder
|
| 520 |
|
|
|a This thought-provoking book covers the full range of psychopharmacologic practice in textbook fashion, offering a fresh and comprehensive self-examination. Unlike conventional texts of psychopharmacology, this text speaks directly to clinicians who have started to question the limitations of psychopharmacologic claims and the rigid confines of DSM-5 diagnoses. Drawing from their clinical and research experience as well as new literature, the well-published authors provide a new perspective that encourages readers to reevaluate established practices and embrace that medication is just one component of treatment and has limits. The book could be used by psychiatric residents in their course of study, by clinical psychology students taking a psychopharmacology course, or by psychiatrists curious to get a readable but comprehensive look at new critical viewpoints in psychopharmacology that have changed since they were taught. Many neuroscience students who are looking for a review of clinical effects to guide their basic research may also find the proposed text more useful than those texts that collate clinical trials. Current texts are for specialized scientists or are part of multi-authored texts which list drugs alphabetically with no conceptual framework, or books that pretend that each biochemical drug property has a clear and known clinical result presented in cartoon style. Some lesser known texts for psychology or nursing students are not authoritative. Others aimed at patients or families are too simplistic for clinicians. The authors goal was to create a unified text expressing their view of psychopharmacology, its evidence base, the unity of its essential principles, and its independence of DSM or ICD diagnosis. Several new history books describe the "rise and fall" of psychopharmacology, the corruption of big pharma and the failure of large controlled clinical trials. Psychopharmacology Reconsidered: A Concise Guide Exploring the Limits of Diagnosis and Treatment ensures that young clinicians are aware of and understand this critical zeitgeist but aware also of the essential core of psychopharmacology and the evidence upon which it rests.
|
| 650 |
|
0 |
|a Psychopharmacology.
|
| 650 |
|
7 |
|a Psychopharmacology
|2 fast
|
| 700 |
1 |
|
|a Lichtenberg, Pesach,
|e author.
|
| 776 |
0 |
8 |
|i Print version:
|a Belmaker, Robert Haim
|t Psychopharmacology Reconsidered
|d Cham : Springer International Publishing AG,c2023
|z 9783031403705
|
| 856 |
4 |
0 |
|u https://holycross.idm.oclc.org/login?auth=cas&url=https://link.springer.com/10.1007/978-3-031-40371-2
|y Click for online access
|
| 903 |
|
|
|a SPRING-ALL2023
|
| 994 |
|
|
|a 92
|b HCD
|